Evidence map›Paper›PMID 20373128›Full record

Trial reportJournal of thrombosis and thrombolysis2011

Inflammatory response to percutaneous coronary intervention in stable coronary artery disease.

Peter S Munk, Unni M Breland, Pål Aukrust, Oyvind Skadberg, Thor Ueland, Alf I Larsen

Registry-linked trialAbstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05739929 (Colchicine Protective Effect in Patients Undergoing Elective Percutaneous Coronary Intervention), which is not on this map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05739929 phase3unknown statusnot on this mapstarted 2023, after this paper: background citation

Colchicine Protective Effect in Patients Undergoing Elective Percutaneous Coronary Intervention (COLCHICINE-PROTECT) A Randomized, Placebo-controlled, Double-blind Clinical Trial

TypeinterventionalSponsorHelwan UniversityRan2023 to 2024Enrolled400ConditionsCoronary Artery DiseaseArmsColchicine 0.5 MG Oral Tablet, Placebo
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Pentraxin 3 in Cardiovascular Disease.Frontiers in immunology · 2019
    Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Peter S MunkDepartment of Cardiology, Stavanger University Hospital, Postbox 8100, 4068 Stavanger, Norway. munk@lyse.net
Unni M Breland
Pål Aukrust
Oyvind Skadberg
Thor Ueland
Alf I Larsen
Stavanger University Hospital · NOUniversity of Oslo · NOOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Percutaneous coronary intervention (PCI) can be regarded as a model for mechanical induced plaque rupture. The objective of this study was to evaluate the inflammatory response to PCI in stable coronary artery disease (CAD) by analysing plasma levels of a wide range of inflammatory mediators. Consecutively, we included 36 patients with stable angina pectoris after successful revascularization by PCI with implantation of a bare metal stent (BMS) or a drug eluting stent (DES). Patients were followed for 7 days with serial measurements of inflammatory mediators in plasma. C-reactive protein (CRP) and Pentraxin 3 showed a statistical significant early increase after PCI peaking at 3 days and 3 h, respectively. Vascular cell adhesion molecule-1 (VCAM-1) increased significantly with a peak at 3 days, while E-selectin showed a statistical significant gradual decrease. Markers of platelet mediated inflammation showed increasing (CD40 ligand) and decreasing (P-selectin) levels after PCI. While monocyte chemoattractant protein, CCL21 and CXCL16 increased rapidly in response to PCI, Interleukin-8, CCL19 and RANTES decreased. Patients with DES had significantly lower levels of VCAM-1 and RANTES compared to those with BMS. A femoral access site was associated with higher CRP levels than a radial access site. The use of glycoprotein-IIb/IIIa-inhibitors was associated with significantly higher CD40L and RANTES levels. Our findings underscore the complex nature of the inflammatory responses during PCI in stable CAD, and suggest that simultaneous measurements of several markers may be needed to characterize these PCI-related responses. The responses were only in a minor degree influenced by stent type, access site and the use of glycoprotein-IIb/IIIa-inhibitors.

Indexed as

AngioplastyDrug-Eluting StentsAgedAngina PectorisCD40 LigandCoronary Artery DiseaseC-Reactive ProteinCytokinesE-SelectinFemaleFollow-Up StudiesHumansInflammationInflammation MediatorsMaleMiddle AgedCD40 LigandC-Reactive ProteinCytokinesE-SelectinInflammation MediatorsPentraxinsP-SelectinSerum Amyloid P-ComponentVascular Cell Adhesion Molecule-1

Identifiers

PMID20373128
OpenAlexW2026214112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.